跳至主要内容
临床试验/NCT02346630
NCT02346630撤回4 期

The Effect of Combining Robotic-Assisted Therapy With Levodopa/Carbidopa in Chronic Post-Stroke Upper-Limb Hemiparesis

Ross D. Zafonte, MD1 个研究点 分布在 1 个国家开始时间: 2015年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
撤回
发起方
试验地点
1
主要终点
Change in Upper Extremity Score of the Fugl-Meyer Assessment (FM-UE) at 1 month

研究概览

简要总结

Stroke is the leading cause of acquired long-term disability in adults in developed countries. Despite aggressive rehabilitation, lasting upper extremity impairment remains in the majority of stroke survivors. It is hypothesized that enhancing neuroplasticity through the combination of drug therapy and physical therapy could enhance outcomes for stroke survivors. The combination of levodopa and intensive physical therapy shows promise in enhancing the functional motor recovery of stroke patients during the sub-acute and chronic period without reported significant side effects. Robotic-aided training is a promising tool that has the potential to deliver high-intensity, task-oriented, reproducible therapy that can decrease the burden on a therapist. Since the evidence behind dopaminergic potentiation of neuroplasticity and stroke recovery is promising, it is the investigators aim to combine dopaminergic drug therapy with highly intensive robotic-assisted therapy to provide superior upper extremity functional recovery over traditional stroke rehabilitation.

详细描述

Every year, approximately 795,000 people suffer a new or recurrent stroke in the United States, meaning that every 40 seconds someone has a stroke. In the United States, stroke is the third most frequent cause of death and the leading cause of lasting hemiparesis and adult disability. Since the prevalence of stroke increases with age, and since the world population is aging, the incidence of stroke is expected to rise in the coming years. This will become a significant societal burden since the care of stroke survivors is costly, to the individual and to society.

Post-stroke upper extremity (UE) impairment usually implies initial weakness, with subsequent diminished dexterity and limitation or incapacity for reaching, transport and grasping movements since the onset. Survivors may regain partial or, less often, complete muscle strength in the affected UE during the recovery process. However, a persistent degree of weakness and evolution to secondary complications as spasticity (characterized by increased flexor hypertonia), shoulder pain and contractures is frequent. These additional issues are associated with greater impairment, worse function and lower health-related quality of life. Treatment interventions for hemiparesis after stroke usually include stretching, strengthening of antagonist muscles, splinting, oral medications, and focal injections (phenol or botulinum toxin) and intrathecal baclofen. However, the amount, intensity and length of therapies still need further investigation. Despite adequate traditional treatment, a high number of patients are still permanently limited as a consequence of stroke. Based on motor learning theories, recent studies have demonstrated that intensive, repetitive, task-oriented therapies can help the paretic extremity "relearn" how to perform movements that were lost after brain damage.

ROBOTIC-ASSISTED UPPER-LIMB TRAINING WITH ARMEO®

Current evidence has shown that rehabilitation without specific training will not result in measurable outcomes. Factors such as intensity and specificity of motor training are important to achieve recovery of motor function, especially in the chronic phase of the stroke. There is robust evidence that highly-repetitive movement rehabilitation could improve motor and functional ability, based on its role in motor learning processes.Robotic devices have become a very important area of research because of their capacity to achieve high-intensity and specificity therapies.

In this proposed project, we plan to use the Armeo robotic system to deliver motor training therapy. The Armeo system is an adjustable arm orthosis that has received FDA 510k exemption. It passively counterbalances the weight of the arm, thereby reducing the effort required by the paretic arm to overcome gravity. The device is able to augment feedback through a virtual environment (i.e. computer games). The tasks presented in the virtual environment are designed to achieve functional movements, i.e. the subject has to perform tasks such as reaching for objects as part of the game. Gravity compensation, which can reduce the level of difficulty of performing an activity, facilitates active arm movement, especially when it involves training in grasping and reaching. By using the Armeo system, we hope to achieve repetitive training of reach, grasp, and release in an engaging environment that can be adapted to individual capabilities. We also expect to enable stroke survivors whose motor weakness may have excluded them from performing repetitive therapy tasks to participate in this study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female, community dwelling, age 18-
  • First episode of stroke.
  • Diagnosis of chronic ischemic stroke at least six months before study enrollment resulting in objective motor upper-extremity impairment as demonstrated during physical/neurological examination.
  • Score of 15-55 out of 66 on the arm motor Fugl-Meyer scale.
  • The ability to extend ≥ 10 degrees at metacarpophalangeal and interphalangeal joint of all digits.
  • Signed written informed consent.

排除标准

  • Intracranial hemorrhages.
  • Pregnancy, planning to become pregnant or breast-feeding.
  • History of seizures within the previous six months.
  • Previous residual motor deficit in the affected side.
  • Treatment with Botox injections in the affected arm in the previous 6 months.
  • Cognitive impairment that may interfere with understanding instructions for motor tasks and assessment tools.
  • Other major neurologic disorder (Parkinson's disease).
  • Major depression defined by the Patient Health Questionnaire, other major psychiatric pathology, dementia, agitation (defined as a score of >21 on the Agitated Behavior Scale) or another uncooperative behavior.
  • Inability to operate the Armeo system (which will be assessed during the calibration process). Subjects must have sufficient range of movement to enable calibration of the virtual workspace.
  • Contraindications for Levodopa/ Carbidopa:
  • Hypersensitivity to levodopa, carbidopa or any component of the formulation.
  • Use of monoamine oxidase inhibitors (MAOIs) within prior 14 days. Treatment with tricyclic antidepressants, antipsychotics, sapropterin, selective serotonin reuptake inhibitors (SSRIs), pimozide, benzodiazepines, amantadine, methylphenidate, dopamine-agonists or neuroleptic drugs when inclusion or the month before.
  • Narrow-angle glaucoma.
  • Suspicious, undiagnosed skin lesions or a history of melanoma.
  • Presence of metallic hardware in close contact to the discharging coil (cochlear implants, aneurism clips, brain implants, internal pulse generator, medication pumps).
  • Contemporary participation in another interventional trial focused on the impaired arm recovery.
  • Drug or alcohol abuse in the last 3 years.
  • A terminal medical diagnosis with survival < 1 year.
  • End-stage or uncompensated hepatic, cardiovascular, cerebrovascular, endocrine, renal, digestive, hematologic or pulmonary disease. Active ulcer disease.

研究组 & 干预措施

Levodopa / Carbidopa + Armeo

Active Comparator

Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks. Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.

干预措施: Levodopa / Carbidopa (Drug)

Levodopa / Carbidopa + Armeo

Active Comparator

Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks. Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.

干预措施: Armeo (Device)

Placebo + Armeo

Placebo Comparator

Placebo capsules daily for 3 weeks. Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.

干预措施: Placebo (Drug)

Placebo + Armeo

Placebo Comparator

Placebo capsules daily for 3 weeks. Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.

干预措施: Armeo (Device)

结局指标

主要结局

Change in Upper Extremity Score of the Fugl-Meyer Assessment (FM-UE) at 1 month

时间窗: month 1

FM-UE is an ordinal scale with scores ranging from 0 to 66 for upper-limb motor performance. It is composed of 33 items. FM-UE is a measure of upper-extremity motor impairment including coordination and speed.

次要结局

  • Wolf Motor Function Test (WMFT)(month 1)
  • Computer Measures on the Armeo Robot(month 1)
  • Veteran's Rand 36(month 1)
  • Hand Dynamometry(month 1)
  • Physical Examination(week 1)
  • Modified Ashworth Scale(month 1)
  • Analysis of Muscle Activation Patterns During Upper Extremity Movements(month 1)
  • Transcranial Magnetic Stimulation Assessment (TMS)(month 1)

研究者

发起方
Ross D. Zafonte, MD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Ross D. Zafonte, MD

Principal Investigator

Spaulding Rehabilitation Hospital

研究点 (1)

Loading locations...

相似试验